Conference Reports for NATAP
Conference on Retroviruses
and Opportunistic Infections (CROI)
Boston, Massachusetts
March 4-7, 2018
Back
 
Impact of Raltegravir Intensification of first-line ART on IRIS in the REALITY trial (Reduction of EArly mortaLITY in HIV-infected adults and children starting ART)
Reported by Jules Levin
CROI 2018 March 4-7 Boston, MA
Diana M Gibb on behalf of the REALITY trial team